Literature DB >> 19180141

The thrombotic thrombocytopenic purpura and hemolytic uremic syndromes: overview of pathogenesis (Experience of The Oklahoma TTP-HUS Registry, 1989-2007).

James N George1.   

Abstract

The Oklahoma TTP (thrombotic thrombocytopenic purpura)-HUS (hemolytic uremic syndrome) Registry, an inception cohort of 382 consecutive patients with TTP-HUS, provides a complete community perspective of these syndromes. TTP is the diagnostic term used for all adults, with or without neurologic or renal abnormalities; it is typically an acquired disorder; it may rarely result from congenital ADAMTS13 deficiency. HUS is the term used for children who have renal failure, most often caused by Escherichia coli O157:H7 infection; it may rarely result from congenital abnormalities of complement regulation. Clinical categories related to associated conditions and potential etiologies provide a structure for describing pathogenesis of the acquired syndromes. (1) Following allogeneic hematopoietic stem cell transplantation; a disorder primarily affecting kidneys described as transplantation-associated thrombotic microangiopathy. (2) Pregnancy-associated; pregnancy is a prominent risk factor for the development of TTP. (3) Drug-associated; acute, immune-mediated systemic syndromes and also dose-dependent renal toxicity. (4) Bloody diarrhea prodrome, suggesting an enteric infectious etiology. (5) Presence of an additional autoimmune disorder. (6) Idiopathic. A severe deficiency of ADAMTS13 activity contributes to the pathogenesis of many idiopathic patients and also some patients who present during pregnancy, with bloody diarrhea, or who have additional autoimmune disorders.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19180141     DOI: 10.1038/ki.2008.609

Source DB:  PubMed          Journal:  Kidney Int Suppl        ISSN: 0098-6577            Impact factor:   10.545


  12 in total

Review 1.  Guidelines for the management and investigation of hemolytic uremic syndrome.

Authors:  Takashi Igarashi; Shuichi Ito; Mayumi Sako; Akihiko Saitoh; Hiroshi Hataya; Masashi Mizuguchi; Tsuneo Morishima; Kenji Ohnishi; Naohisa Kawamura; Hirotsugu Kitayama; Akira Ashida; Shinya Kaname; Hiromichi Taneichi; Julian Tang; Makoto Ohnishi
Journal:  Clin Exp Nephrol       Date:  2014-08       Impact factor: 2.801

2.  Effects of subinhibitory concentrations of menthol on adaptation, morphological, and gene expression changes in enterohemorrhagic Escherichia coli.

Authors:  Elad Landau; Roni Shapira
Journal:  Appl Environ Microbiol       Date:  2012-05-25       Impact factor: 4.792

3.  HELLP Syndrome at 17 Weeks Gestation: A Rare and Catastrophic Phenomenon.

Authors:  Erica L Berry; Sara N Iqbal
Journal:  J Clin Gynecol Obstet       Date:  2014-12

4.  Etiology and Outcomes of Thrombotic Microangiopathies.

Authors:  Guillaume Bayer; Florent von Tokarski; Benjamin Thoreau; Adeline Bauvois; Christelle Barbet; Sylvie Cloarec; Elodie Mérieau; Sébastien Lachot; Denis Garot; Louis Bernard; Emmanuel Gyan; Franck Perrotin; Claire Pouplard; François Maillot; Philippe Gatault; Bénédicte Sautenet; Emmanuel Rusch; Matthias Buchler; Cécile Vigneau; Fadi Fakhouri; Jean-Michel Halimi
Journal:  Clin J Am Soc Nephrol       Date:  2019-03-12       Impact factor: 8.237

5.  Oxidative modification of von Willebrand factor by neutrophil oxidants inhibits its cleavage by ADAMTS13.

Authors:  Junmei Chen; Xiaoyun Fu; Yi Wang; Minhua Ling; Brad McMullen; John Kulman; Dominic W Chung; José A López
Journal:  Blood       Date:  2009-10-07       Impact factor: 22.113

6.  Isoniazid causing drug-induced thrombocytopenia.

Authors:  Donald R Laub
Journal:  Eplasty       Date:  2011-06-08

7.  Decrease in Shiga toxin expression using a minimal inhibitory concentration of rifampicin followed by bactericidal gentamicin treatment enhances survival of Escherichia coli O157:H7-infected BALB/c mice.

Authors:  Elias A Rahal; Natalie Kazzi; Ahmad Sabra; Alexander M Abdelnoor; Ghassan M Matar
Journal:  Ann Clin Microbiol Antimicrob       Date:  2011-09-12       Impact factor: 3.944

8.  Retrospective and Systematic Analysis of Causes and Outcomes of Thrombotic Microangiopathies in Routine Clinical Practice: An 11-Year Study.

Authors:  Nicolas Henry; Chloé Mellaza; Nicolas Fage; François Beloncle; Franck Genevieve; Guillaume Legendre; Corentin Orvain; Anne-Sophie Garnier; Maud Cousin; Virginie Besson; Jean-François Subra; Agnès Duveau; Jean-François Augusto; Benoit Brilland
Journal:  Front Med (Lausanne)       Date:  2021-02-26

9.  Cyclophosphamide-rescued plasmapheresis-unresponsive secondary thrombotic thrombocytopenic purpura caused by Sjögren's syndrome.

Authors:  Ting-Yun Lin; Chun-Cheng Chang; Chun-Chao Chang; Jui-Yu Yuan; Hsi-Hsien Chen
Journal:  Arch Med Sci       Date:  2012-10-08       Impact factor: 3.318

10.  End-stage kidney disease due to haemolytic uraemic syndrome--outcomes in 241 consecutive ANZDATA registry cases.

Authors:  Wen Tang; Janaki Mohandas; Stephen P McDonald; Carmel M Hawley; Sunil V Badve; Neil Boudville; Fiona G Brown; Philip A Clayton; Kathryn J Wiggins; Kym M Bannister; Scott B Campbell; David W Johnson
Journal:  BMC Nephrol       Date:  2012-12-03       Impact factor: 2.388

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.